Omeza

Omeza is a skin health company with a mission to restore skin integrity for people suffering from serious skin issues and optimize skin quality for everyone. The end users of Omeza are individuals who suffer from chronic wounds or are at risk of developing chronic wounds due to aging, exacerbated by comorbidities such as diabetes, obesity, chronic venous insufficiency, peripheral artery disease, and autoimmune diseases. Current standard care is inadequate, with biofilm impeding wound closure, excessive debridement, and insufficient provider training leading to stalled wound healing and expensive, often ineffective advanced wound care treatments. These wounds frequently result in costly hospitalizations and amputations. Its developed OCM is the first drug-device combination product administered by HCPs, providing comprehensive treatment across all stages of wound healing; reducing biofilm formation, decreasing inflammation, promoting proliferation, and supporting remodeling.